53 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
3 PEGASUS and PRINCE studies and the long-term extension study reinforcing the safety and efficacy profile of EMPAVELI in PNH for up to three years … portion of right of use liabilities
Total current liabilities
Long-term liabilities:
Long-term development liability
Convertible senior notes
Right
8-K
EX-1.1
ncv3qsa
1 Nov 23
Entry into a Material Definitive Agreement
7:59am
8-K
EX-99.1
9tdt0mm32mmvqdj5m6
5 Oct 23
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
7:15am
8-K
EX-99.1
25mpmw
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
8-K
82g2quo7
24 Aug 22
Other Events
8:15am
8-K
EX-1.1
n7nbd
24 Mar 22
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8:18pm
424B5
fiemynuyjwcvwin02
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
fykha30efrkye w40c5y
23 Mar 22
Prospectus supplement for primary offering
5:14pm